RVX.TO - Resverlogix Corp.

Toronto - Toronto Delayed Price. Currency in CAD
3.4500
+0.0500 (+1.47%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.4000
Open3.4100
Bid3.4400 x 0
Ask3.4700 x 0
Day's Range3.3800 - 3.4500
52 Week Range1.1100 - 4.9400
Volume86,054
Avg. Volume110,738
Market Cap691.135M
Beta (3Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-0.6040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.57
  • CNW Group10 days ago

    IIROC Trade Resumption - RVX

    IIROC Trade Resumption - RVX

  • GlobeNewswire10 days ago

    Resverlogix Announces Pricing of Unit Offering

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO)  is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at $4.00 per Unit.  Each Unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of $4.60 per underlying common share for a period of 4 years from the first closing of the Offering.

  • CNW Group10 days ago

    IIROC Trading Halt - RVX

    IIROC Trading Halt - RVX

  • GlobeNewswire11 days ago

    Resverlogix Announces Proposed Offering of Units

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in  the  provinces of Ontario, Alberta and British Columbia in connection with a proposed marketed offering of units of the Company (“Units”), comprised of common shares and common share purchase warrants (the “Offering”). The number of Units to be distributed, the price and composition of each Unit, the minimum and maximum size of the Offering, and the exercise price and term of each warrant will be determined by negotiation between the Company and the Agent (as defined herein) in the context of the market.

  • GlobeNewswire19 days ago

    Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today the recent publication of an article titled: “Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension” in the high-impact, peer-reviewed medical journal, American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society. A Phase 2 clinical trial – studying apabetalone as a potential therapy for pulmonary arterial hypertension (PAH) – is expected to initiate following completion of an already planned pilot study to begin in the first half of 2019. “We are extremely pleased that our collaborative work resulted in this high-profile publication highlighting the potential of apabetalone and BET inhibition in the treatment of PAH and other diseases,” said Dr. Ewelina Kulikowski, Senior Vice President, Research & Development of the Company.

  • GlobeNewswire23 days ago

    Resverlogix Announces 3-Month Loan Extension

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that it has entered into an amending agreement with Third Eye Capital (acting as agent for a syndicate of lenders) to extend the maturity date of the Company’s senior secured term loan by three months to August 4, 2019. In addition, the lenders agreed to reduce the minimum cash balance that the Company is required to maintain from US$5 million to US$3 million. Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.

  • Zacks Small Cap Researchlast month

    RVX: 250 Events Reached!

    Resverlogix Corp. (RVX.TO) reported today that it has observed the targeted 250 events in its Phase III BETonMACE trial which began in November 2015. The study has a primary endpoint of time to first occurrence of Major Adverse Cardiac Event (MACE)1. The study will also examine kidney function in chronic kidney disease (CKD) patients as well as cognitive function in patients over 70 years of age.

  • GlobeNewswirelast month

    Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces that BETonMACE, the Company’s event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac events (MACE), strictly defined as cardiovascular death, non-fatal myocardial infarction and stroke, moving the trial towards completion. Successful data from this trial would enable Resverlogix to proceed towards the regulatory approval and commercialization of its lead drug, apabetalone. “Resverlogix staff and stakeholders have worked diligently for the past 18 years to attain this extremely exciting goal,” said Donald McCaffrey, President and CEO of Resverlogix.

  • Zacks Small Cap Researchlast month

    RVX: BETonMACE Final Event Expected April 2019

    Resverlogix Corp (RVX.TO) provided an update of the financial and operational results for the period of November 1, 2018 to January 31, 2019. During the quarter, the company raised additional funds in private placements, received its eighth positive DSMB recommendation, was published in the Atherosclerosis journal and after quarter end received additional funding to pursue apabetalone in pulmonary arterial hypertension (PAH). The 35% decline in R&D from 3Q:18’s $11.9 million was attributable to lower clinical costs as the BETonMACE trial winds down.

  • GlobeNewswire2 months ago

    Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

    CALGARY, Alberta, April 01, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland.

  • GlobeNewswire2 months ago

    Resverlogix Announces $15.1 Million of Private Placements

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today it has closed private placements of approximately 4.5 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (“Hepalink”) and 0.6 million equity units to other subscribers at a price of $3.00 per unit for gross proceeds of approximately $15.1 million (US$11.3 million). Each unit was comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant is exercisable at a price of $3.21 per share for a period of three years from the closing of the private placements.

  • GlobeNewswire2 months ago

    Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

    CALGARY, Alberta, March 27, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has.

  • GlobeNewswire2 months ago

    Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher

    CALGARY, Alberta, March 18, 2019 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement of a $2.9 million project led by academic.

  • GlobeNewswire2 months ago

    Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

    Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s investigational new drug application for ZEN-3694, a novel and differentiated  bromodomain and extra-terminal domain inhibitor (“BETi”), for triple negative breast cancer (“TNBC”) in combination with talazoparib, a poly ADP ribose polymerase inhibitor (“PARPi”).

  • GlobeNewswire2 months ago

    Resverlogix Announces Participation at Prominent Industry and Investor Conferences

    CALGARY, Alberta, March 11, 2019 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading industry and investor conferences.

  • GlobeNewswire4 months ago

    Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today it has closed a private placement of approximately 2.2 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (“Hepalink”) at a price of $3.00 per unit for gross proceeds of approximately $6.6 million (US$5 million). Each unit was comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant is exercisable at a price of $3.21 per share for a period of three years from the closing of the private placement.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Cotinga Pharmaceuticals, Aurinia Pharmaceuticals, Resverlogix and Hamilton Thorne

    NEW YORK, NY / ACCESSWIRE / January 15, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire5 months ago

    Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announces the independent Data and Safety Monitoring Board (DSMB) has completed an eighth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk cardiovascular disease (CVD) patients and recommended the study continue without modification. The DSMB reviewed available safety data and commented that no safety concerns were identified.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Acerus Pharmaceuticals, GeneNews, Resverlogix and Hamilton Thorne

    NEW YORK, NY / ACCESSWIRE / December 5, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswire6 months ago

    Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

    CALGARY, Alberta, Nov. 28, 2018 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone.

  • GlobeNewswire7 months ago

    Resverlogix Closes $13.5 Million Private Placement

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today it has closed a private placement of approximately 4.5 million equity units at a price of $3.00 per unit for gross proceeds of approximately $13.5 million (US$10.3 million). Each unit was comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant is exercisable at a price of $3.10 per share for a period of three years from the closing of the private placement.

  • ACCESSWIRE7 months ago

    Today's Research Reports on GeneNews, Medicure, Aphria and Resverlogix

    NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...